Case summary
36-year-old male with chronic kidney disease underwent a live related renal transplantation on February 2010. He received basiliximab induction and was started on prednisolone 20 mg OD, mycophenolate sodium (MPA) 360 mg TDS and cyclosporine (CYC) 100 mg BD, but developed graft dysfunction, for which graft biopsy was done on post-operative day (POD) 8, showed acute cellular rejection, Banff, grade 1 and was treated with 5 doses of IV methylprednisolone 500 mg. Cyclosporine was changed to tacrolimus with dose of 2 mg BD. After recovery of graft function the DJ stent was removed on POD 12 and he was discharged on POD 18 with serum creatinine of 1.25 mg/dl. Subsequently on follow up he developed graft dysfunction in May 2012, graft biopsy revealed acute T-cell mediated rejection which was treated with 3 doses of IV methyl prednisolone with graft functioning settling at Serum creatinine 1.34 mg% with tacrolimus through levels around 5.5 ng/dl.
In August 2013, he again presented with acute graft dysfunction with s creatinine of 1.9 mg/dl. He was asymptomatic, non-oliguric.
Doppler was normal and his had appropriate tacrolimus level (4.3 ng/ml), urine for decoy cells and urine cultures were negative with 1.2 gm of protein in 24 h urine. Ultrasound (USG) showed mild splitting of pelvicalyceal system (PCS). Renal allograft biopsy was negative for C4d but showed mild tubulitis with interstitial inflammation. There were no viral inclusion bodies and SV-40 antigen was negative in immunohistochemistry. No active intervention was done and discharged with a creatinine of 1.6 mg/dl. However, his renal function showed worsening with gradual rise to 2.5 mg% in December 2013. USG revealed dilatation of the PCS and proximal ureter with gradual thickening of the ureteric wall in its entire length up to retro vesicle junction ( Fig. 1 ). Multiple urine smears and cultures for mycobacterium were negative in addition to urine TB polymerase chain reaction (PCR). Centrifuged urine for malignant cells was also negative although urine decoy cells were negative, BKV in serum and urine by qualitative PCR came as positive.
In view of outflow tract obstruction which was considered the cause for graft dysfunction, patient was advised for nephrostomy with ante grade stenting or surgical resection with ureteric reimplantation. Patent underwent nephrostomy with ante grade stenting along with modification in his immunosuppression, his maintenance immunosuppression was adjusted; Mycophenolate Mofetil (MMF) was withdrawn and changed over to azathioprine along with low dose of ciprofloxacin at a dose of 250 mg bd, tacrolimus dose was reduced to maintain a trough level of 4.0 ng/ml along with h prednisolone dose of 7.5 mg OD. He was closely followed up with serial ultrasound of the graft and urinary BKV PCR. On follow up his renal function slowly improved with gradual resolution of hydronephrosis and thickening of ureteric wall. DJ stent was removed after 3 months with no residual hydronephrosis or ureteric thickening on follow up ultrasound (Fig. 2) . Qualitative PCR for BKV in serum and urine became negative after 8 months and 12 months of follow up, respectively. Last follow up in June 2016 showed his serum creatinine was 1.3 mg/dl with no hydrourteronephrosis. There was no evidence of hepatitis or bone marrow suppression on follow up with the use of azathioprine.
Discussion
BKV-associated allograft ureteric stenosis is well known but a rare complication usually presenting within 6 months after renal transplant. 1 The location of the stenosis is usually seen in the distal part of the ureter, especially around the site of anastomosis at the uretero-vesical junction 2 which was also evident in our patient. The presence of BKV induced histologic changes in the ureteric biopsy is necessary but technically difficult. Stenosis with any level of quantification of BK viruria or viremia is confirmatory. Since in our patient the stenosis developed after 3 years of renal transplant hence was less likely due to technical or tuberculosis or malignancy as repeated urine smears and cultures were negative for mycobacterium along with urine TB polymerase chain reaction (PCR). Centrifuged urine for malignant cells was also negative. His BKV in serum and urine by qualitative PCR were positive along with ultrsounlogical evidence of thickening more marked in distal ureter up to urterovesical junction was considered due to BKV urteritis. Probable reason for late presentation in our case could be due to recurrent usage of steroids for treatment of acute rejection, which could have contributed to reactivation of BKV.
The reduction of immunosuppression may be helpful in early course of disease where actual stenosis has not developed and viremia is present preventing development of BKV nephropathy. Ureteral stent placement at this stage may increase the risk for developing BK viremia due to viral replication. 3, 4 In late presentation of BKV along with ureteric stenosis may require not only modification of immunosuppression but also placement of percutaneous nephrostomy tube for decompression either anterograde stenting or a surgical procedure. 5 Our case was managed with modification of immunosuppression along with DJ stenting. A close follow up with serial ultrasound of the graft for hydronephrosis and urinary BKV PCR for viurea. On follow up his renal function slowly improved with gradual resolution of hydronephrosis and thickening of ureteric wall. Although biopsy could not be performed at the site of obstruction, there was a strong link between BKV infection and stenosis which did show improvement after adjustment of immunosuppression and DJ stenting which on removal after 3 months showed no further worsening of his renal function along with serological improvement suggesting that late onset BKV-associated renal allograft dysfunction due to proximal ureteric stenosis responds to reduction of immunosuppressive regimen along with radiological intervention (Fig. 2) . Early diagnosis and treatment at this stage shows good response to intervention and is thus mandated to screen for BKV in renal transplant recipients with graft dysfunction especially with hydronephrosis and help in clinical recovery. 6 
Conclusion
Modification in immunosuppression along with timely DJ stenting of the BKV associated ureteric stenosis can help in restoring the graft function and better long-term graft outcome. 
